Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004 Jul; 89(7):3319-25.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.